Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Large Drop in Short Interest

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 774,700 shares, a decrease of 79.0% from the October 31st total of 3,690,000 shares. Based on an average daily volume of 15,910,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 3.5% of the shares of the company are short sold.

Insider Buying and Selling at Tevogen Bio

In other Tevogen Bio news, insider Neal Flomenberg sold 1,078,600 shares of the business’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the sale, the insider now owns 4,254,302 shares in the company, valued at approximately $6,891,969.24. The trade was a 20.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 56.60% of the stock is currently owned by company insiders.

Institutional Trading of Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. bought a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned 0.13% of Tevogen Bio at the end of the most recent reporting period.

Tevogen Bio Trading Down 4.4 %

Shares of Tevogen Bio stock traded down $0.06 on Friday, reaching $1.31. 1,144,755 shares of the stock were exchanged, compared to its average volume of 4,936,248. The business has a 50 day moving average price of $1.29 and a two-hundred day moving average price of $0.90. Tevogen Bio has a twelve month low of $0.26 and a twelve month high of $21.09.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.